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ductal carcinomas in situ. Axillary lymph node involvement 
was seen in 34.3%. Most of the tumors were estrogen positive 
(68.75%) and progesterone positive (65.6%). A systemic 
therapy was given in 81.25% of the patients. After second 
breast conserving therapy or no surgery re- RT was given to 
the involved quadrant using external- beam ports (electrons 
or photons) with doses of 50-60Gy in 2Gy per fraction. The 
median age at local relapse was 65.8 years. A second breast 
conserving therapy was performed in 90.7% of the women, 
9.3% had no surgery and were re-irradiated to a dose of 
60Gy. A systemic therapy was given in 84.3%.Survival and 
local control were calculated by the Kaplan-Meier actuarial 
method. 
 
Results: A total of 32 patients were retrospectively analyzed. 
The median follow up of survivors was 181 months from first 
diagnosis and 33 month from second RT. At the time of 
analysis 4 patients had died. The median time between first 
and second RT was 9.9 years (range 1.8- 20.3). Fifteen years 
after first diagnosis 86% of the patients were still alive. Four 
women died, 3 on cancer. After second RT only one acute G2 
toxicity of the skin was reported (desquamation).Late 
toxicity was scored using the LENT- SOMA Score Criteria. 
Lymphedema (G1) of the ipsilateral arm was observed in 
3.1%, 3.1% reported on intermittent pain in the breast and 
9.3% presented with an asymptomatic breast edema. The 
highest rate of late toxicity was G2 fibrosis in 18.7%.No G3 or 
G4 toxicity was observed.  
 
Conclusion: Carefully planned re-RT of the involved breast 
quadrant is a safe alternative therapy for those women who 
did not gave their consent to the recommended mastectomy. 
No second local relapse was detected after re-RT. Acute side 
effects were low. In 18.7% of the women fibrosis G2 was 
detected. 
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Purpose or Objective: Cancer en cuirasse is a severe 
locoregional manifestation of breast cancer, usually occurring 
after a number of treatment failures. Treatment options are 
limited. One hundred and sixty-nine patients were treated 
with re-irradiation and hyperthermia (reRT+HT) from 1982 till 
2006. Response and toxicity rates as well as the locoregional 
progression free interval were determined to assess the 
palliative value of this treatment. 
 
Material and Methods: All patients had received extensive 
previous treatments, including surgery, irradiation (median 
dose 50Gy with or without boost) and systemic treatments.. 
Seventy-five percent of patients had 1-7 previous 
locoregional recurrence episodes; 68% were treated with 
systemic therapies and 27% underwent salvage surgery.  
At start of re-RT+HT the tumor area comprised > 3/4 
ipsilateral chest wall in 54% of patients. Fifty-two percent 
had areas of ulcerating tumor. Distant metastases were 
present in 45% of patients. reRT consisted typically of 8x4Gy, 
twice a week or 12x3Gy, four times a week. Superficial 
hyperthermia was applied once or twice a week using 434MHz 
Contact Flexible Microstrip Applicators (CMFA), heating the 
tumor area to 41-43˚C for one hour. 
 
Results: The treatment was well tolerated; 154 patients 
completed treatment, only 15 patients did not, due to 
disease progression in 12, toxicity in 2 and refusal in 1 
patient. Overall clinical response rate was 72% (30% CR; 42% 
PR), while only 6% showed PD. Median follow-up time was 7 
months. The 1-year progression-free-interval was 24% with a 
1-year survival rate of 36%. Acute ≥ grade 3 toxicity occurred 
in 33% of patients and consisted mostly of ulceration and 
dermatitis. The occurrence of radiation ulcera was 
significantly related to the presence of ulcerating tumor 
before the start of the reRT-HT (P=0.004, HR = 4.4). 
 
Conclusion: The combination of re-irradiation and 
hyperthermia is well tolerated and results in high response 
rates despite extensive disease and resistance to previous 
treatments. ReRT+HT is a worthwhile palliative treatment 
option for this patient group who suffer from extensive 
locoregional tumor growth and have a very poor prognosis.  
 
 
Proffered Papers: Clinical 2: Adverse effects in 
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Purpose or Objective: Stereotactic radiotherapy (SRT) of 
brain metastases results in regression of most treated 
metastases, but subsequent lesion growth may occur and is 
caused by either tumor progression or pseudo-progression, 
which is probably a radiation effect on surrounding normal 
brain tissue. It is unknown if active treatment is indicated in 
symptomatic patients, or if it is better to wait for 
spontaneous recovery. The purpose of this study is to 
describe the clinical course of brain metastasis patients 
developing pseudo-progression after SRT to improve clinical 
decision-making. 
 
Material and Methods: Follow-up MRI scans of all patients 
who received SRT of brain metastases from 2009 through 
2012 were reviewed for post SRT lesion growth. Depending on 
the volume of the metastasis, the patients had received one 
fraction of 21Gy, 18Gy, or 15Gy, or three fractions of 8Gy or 
8.5Gy. The GTV-PTV margin was 2mm. Pseudo-progression 
was considered to be the cause of this lesion growth if a 
histological diagnosis of necrosis had become available, if the 
lesion had shown subsequent regression or if two neuro-
radiologists agreed upon this diagnosis based on a review of 
the follow-up perfusion MRI scans. The clinical course of the 
patients with these pseudo-progressive lesions was 
retrospectively studied. 
 
Results: In a total of 237 treated patients we identified 37 
patients with 50 pseudo-progressive lesions. The median 
follow-up of all patients still alive was 40.7 months. The main 
clinical symptoms that were attributed to this lesion growth 
were neurologic deficits, headache and seizures in 19 (51%), 
3 (8%) and 4 (11%) patients respectively (unknown in one). 
Ten patients (27%) had no symptoms attributed to the lesion 
growth and remained asymptomatic afterwards. Of the 19 
patients with neurologic deficits one improved after 
spontaneous regression of the lesion, one improved after 
surgery and 17 did not improve. Two out of the four patients 
with seizures improved with ant-epileptic drugs (AED’s), one 
improved after surgery and one did not improve. Only one of 
the three patients with headache improved with steroids. 
Spontaneous regression of an initially pseudo-progressive 
lesion was observed in 18 patients. Twelve of these 18 
patients had symptomatic pseudo-progression, but only one 
of these 12 patients experienced neurologic improvement 
without treatment. In 6 patients their deaths were related to 
the pseudo-progressive lesion.  
 
Conclusion: Patients with an asymptomatic pseudo-
progressive lesion frequently remain asymptomatic. Patients 
with a symptomatic pseudo-progressive lesion only rarely 
recover spontaneously. Active treatment, such as surgery, 
should be considered for these patients. Therefore, 
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symptomatic pseudo-progression after SRT of brain 
metastases needs to be considered as a serious radiation 
induced toxicity. Reduction of the high dose volume of 
normal brain tissue may prevent this toxicity. 
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Purpose or Objective: Following EBRT for prostate cancer, 
patients can develop aggravation of urinary symptoms mostly 
due to urethral dose. With dose-escalated EBRT it is 
suggested that genitourinary toxicity increases with 
increasing dose. In the experimental arm of the FLAME-trial 
(284 patients) a dose of 77Gy to the entire prostate gland in 
35 fractions was administered, with an integrated boost up to 
95Gy to the macroscopic lesions. No dose constraints for the 
urethra were set during the trial. The objective of this study 
is to evaluate urethral dose parameters, urethra-related 
toxicity and prostate-specific QoL scores for patients treated 
with and without dose-escalated EBRT.  
 
Material and Methods: Between 2009 and 2015, 571 
intermediate and high risk prostate cancer patients were 
enrolled in the FLAME trial, a phase 3, single blind, multi-
center randomized controlled trial (NCT01168479). The 
control arm (287 patients) received a dose of 77Gy to the 
entire prostate gland in 35 fractions. The experimental arm 
(284 patients) received the same dose, but with an 
integrated boost up to 95Gy to the multi-parametric MRI-
based intraprostatic lesion. For this study, the urethra was 
delineated retrospectively on T2 weighted MRI, using a circle 
shape with a diameter of 3 mm, to obtain dose parameters. 
These dose parameters, the Genitourinary Toxicity 
scores(CTCAE v3.0) and the urinary symptoms scale of the 
EORTC QLQ-PR25, were compared for both treatment arms. 
The physician in attendance scored toxicity at baseline, 
weekly during treatment, 4 weeks after treatment and every 
6 months up to 10 years. QoL was filled out 1 week before 
treatment and the next questionnaires were sent to the 
patient every 6 months up to 10 years. Mean differences 
between groups at 1 year of follow-up were calculated using 
an independent samples t-test (dosimetry and QoL), Chi-
square test or Fisher’s exact test (toxicity). Statistical 
significance was considered P<0.01.  
 
Results: Results after analysis of 100 patients (50 patients in 
each treatment arm) with a median follow-up of 22 months 
show for the control arm an average Dmean (mean dose to 
the urethra) of 77.3 ± 0.5 Gy (range 75.9-78.0 Gy), with an 
average Dmax (maximum dose to the urethra) of 79.6 ± 0.8 
Gy (range 78.0-81.3). In the experimental arm, average 
Dmean was 82.0 ± 2.8 Gy (range 77.4-89.0 Gy) and average 
Dmax was 89.7 ± 0.6 Gy (range 80.7-97.7 Gy). For both 
Dmean and Dmax the difference between treatment arms 
was significant (p=0.000). Grade 3 GU toxicity did not occur, 
grade 2 GU toxicity occurred in a subset of patients, although 
no significant difference was found between both treatment 
arms for the separate GU items (table 1). Urinary symptoms-
related QOL was not significantly different across treatment 
arms. 
 
 
Conclusion: Results showed a significant difference in 
urethral dose, but no significant differences in toxicity or 
quality of life when comparing both treatment arms of the 
FLAME trial. 
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Purpose or Objective: Radiotherapy of lung cancer delivers 
quite high doses of radiation to the heart. We explored 
associations between overall survival (OS) and radiation dose 
to heart and its substructures and electrocardiographic (ECG) 
changes. 
 
Material and Methods: We analysed data from 79 patients in 
IDEAL CRT, a phase I/II trial of isotoxic radiotherapy (RT) 
dose escalation trial, sponsored by University College London 
(C13530/A10424). Mean and maximum prescribed doses were 
69 and 75.6Gy calculated as 2Gy fractionation equivalents 
(EQD2, α/β=10Gy). Whole heart, left ventricle (LV), right 
ventricle (RV), right atrium (RA), left atrium (LA) and AV 
node (AVN) were outlined on RT planning scans and 
differential dose volume histograms (DVHs) extracted, 
converting physical DVHs to EQD2s (α/β=3). Patient-to-
patient DVH variability was represented using a small number 
of Varimax-rotated principal components (PCs) explaining 
95% of total variance. ECGs were analysed at baseline, 6 and 
12 months (mo) after treatment, and changes in heart rate 
(HR) recorded, with patients dichotomised according to 
presence or absence of ‘any ECG rhythm change’ (conduction 
abnormalities or ischaemia). OS was modelled using Cox 
regression from the start of treatment. Univariate analysis 
(UVA) and multivariate analysis (MVA) of clinical factors 
included ‘any rhythm ECG change’ at 6 and 12 months, 
change in HR at 6 or 12 months, planning target volume 
(PTV), and prescribed dose (PD). MVA of whole heart 
dosimetric factors included all 7 Heart PCs, PTV, and PD. MVA 
of heart substructures included heart substructure PCs with p 
< 0.2 on UVA having similar dosimetric distributions to 
significant Heart PCs, PTV and PD. 
 
